Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms

Future Medicinal Chemistry

Volumn 6, Issue 1, 2014, Pages 77-90

  Delattin, Nicolas ^a   Cammue, Bruno Pa ^a   Thevissen, Karin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; POLYENE; PYRROLE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANTIFUNGAL ACTIVITY; BIOFILM; FUNGICIDAL ACTIVITY; NONHUMAN; PLANKTON; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; AZOLES; BIOFILMS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGI; POLYENES; REACTIVE OXYGEN SPECIES;

EID: 84891305354     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.189     Document Type: Review

References (134)

1. Lai CC, Tan CK, Huang YT, Shao PL, Hsueh PR. Current challenges in the management of invasive fungal infections. J. Infect. Chemother. 14(2), 77-85 (2008).
2. Butts A, Krysan DJ. Antifungal drug discovery. Something old and something new. PLoS Pathog. 8(9), e1002870 (2012).
3. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science 336(6082), 647 (2012).
4. Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog. 8(4), e1002585 (2012).
5. Hasan F, Xess I, Wang X, Jain N, Fries BC. Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect. 11(8-9), 753-761 (2009).
6. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45(6), 1843-1850 (2007).
7. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int. J. Microbiol. 2012, 528521 (2012).
8. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin. Microbiol. Rev. 17(2), 255-267 (2004).
9. Ramage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6(7), 979-986 (2006).
10. Uppuluri P, Chaturvedi AK, Srinivasan A et al. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 6(3), e1000828 (2010).
11. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130(5), 797-810 (2007).
12. Liu Y, Imlay JA. Cell death from antibiotics without the involvement of reactive oxygen species. Science 339(6124), 1210-1213 (2013).
13. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339(6124), 1213-1216 (2013).
14. Yoshida Y. Cytochrome P450 of fungi: primary target for azole antifungal agents. Curr. Top. Med. Mycol. 2, 388-418 (1988).
15. Kelly SL, Lamb DC, Baldwin BC, Corran AJ, Kelly DE. Characterization of Saccharomyces cerevisiae CYP61, sterold-22-desaturase, and inhibition by azole antifungal agents. J. Biol. Chem. 272(15), 9986-9988 (1997).
16. Kobayashi D, Kondo K, Uehara N et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. 46(10), 3113-3117 (2002).
17. Francois IE, Cammue BPA, Borgers M, Ausma J, Dispersyn GD, Thevissen K. Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Curr. Med. Chem. 5, 3-13 (2006).
18. Yan L, Li M, Cao Y, Gao P, Wang Y, Jiang Y. The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility. J. Antimicrob. Chemother. 64(4), 764-773 (2009).
19. Thevissen K, Ayscough KR, Aerts AM et al. Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast. J. Biol. Chem. 282(30), 21592-21597 (2007).
20. Yan L, Zhang JD, Cao YB, Gao PH, Jiang YY. Proteomic analysis reveals a metabolism shift in a laboratory fluconazole-resistant Candida albicans strain. J. Proteome Res. 6(6), 2248-2256 (2007).
21. Rubio MC, de Ocariz IR, Gil J, Benito R, Rezusta A. Potential fungicidal effect of voriconazole against Candida spp. Int. J. Antimicrob. Agents 25(3), 264-267 (2005).
22. Ferreira GF, Baltazar LD, Santos JR et al. The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Cryptococcus gattii. J. Antimicrob. Chemother. 68(8), 1801-1811 (2013).
23. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46(6), 1773-1780 (2002).
24. Ramage G, Vandewalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46(11), 3634-3636 (2002).
25. Lamfon H, Porter SR, Mccullough M, Pratten J. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study. J. Antimicrob. Chemother. 53(2), 383-385 (2004).
26. Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 50(3), 1021-1033 (2006).
27. Vandenbosch D, Braeckmans K, Nelis HJ, Coenye T. Fungicidal activity of miconazole against Candida spp. biofilms. J. Antimicrob. Chemother. 65(4), 694-700 (2010).
28. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52(1), 357-360 (2008).
29. Nett JE, Sanchez H, Cain MT, Andes DR. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202(1), 171-175 (2010).
30. Mowat E, Lang S, Williams C, Mcculloch E, Jones B, Ramage G. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 62(6), 1281-1284 (2008).
31. Bink A, Vandenbosch D, Coenye T, Nelis HJ, Cammue BP, Thevissen K. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob. Agents Chemother. 55(9), 4033-4037 (2011).
32. Lafleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50(11), 3839-3846 (2006).
33. Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrob. Agents Chemother. 54(10), 4474-4475 (2010).
34. Bink A, Govaert G, Vandenbosch D et al. Transcription factor Efg1 contributes to the tolerance of Candida albicans biofilms against antifungal agents in vitro and in vivo. J. Med. Microbiol. 61(Pt 6), 813-819 (2012).
35. Caffrey P, Lynch S, Flood E, Finnan S, Oliynyk M. Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes. Chem. Biol. 8(7), 713-723 (2001).
36. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl. 1), 7-10 (2002).
37. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46(1), 120-128 (2008).
38. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12(6), 463-470 (2000).
39. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. 37(3), 415-425 (2003).
40. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34(2), 183-188 (1990).
41. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40(2), 279-291 (1996).
42. Gruszecki WI, Gagos M, Herec M, Kernen P. Organization of antibiotic amphotericin B in model lipid membranes. A mini review. Cell. Mol. Biol. Lett. 8(1), 161-170 (2003).
43. Gray KC, Palacios DS, Dailey I et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl Acad. Sci. USA 109(7), 2234-2239 (2012).
44. Te Welscher YM, Van Leeuwen MR, De Kruijff B, Dijksterhuis J, Breukink E. Polyene antibiotic that inhibits membrane transport proteins. Proc. Natl Acad. Sci. USA 109(28), 11156-11159 (2012).
45. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154(1), 76-83 (1986).
46. Phillips AJ, Sudbery I, Ramsdale M. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc. Natl Acad. Sci. USA 100(24), 14327-14332 (2003).
47. Mousavi SA, Robson GD. Oxidative and amphotericin B-mediated cell death in the opportunistic pathogen Aspergillus fumigatus is associated with an apoptotic-like phenotype. Microbiology 150(Pt 6), 1937-1945 (2004).
48. Sangalli-Leite F, Scorzoni L, Mesa-Arango AC et al. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect. 13(5), 457-467 (2011).
49. Blum G, Perkhofer S, Haas H et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52(4), 1553-1555 (2008).
50. Agarwal AK, Rogers PD, Baerson SR et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J. Biol. Chem. 278(37), 34998-35015 (2003).
51. Al-Dhaheri RS, Douglas LJ. Apoptosis in Candida biofilms exposed to amphotericin B. J. Med. Microbiol. 59(Pt 2), 149-157 (2010).
52. Fiori B, Posteraro B, Torelli R et al. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob. Agents Chemother. 55(6), 3031-3035 (2011).
53. Vediyappan G, Rossignol T, d'Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob. Agents Chemother. 54(5), 2096-2111 (2010).
54. Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob. Agents Chemother. 54(8), 3505-3508 (2010).
55. Tobudic S, Lassnigg A, Kratzer C, Graninger W, Presterl E. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases. Mycoses 53(3), 208-214 (2011).
56. Didone L, Oga D, Krysan DJ. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse Candida albicans cells in biofilms. Yeast 28(8), 561-568 (2011).
57. Mukherjee PK, Long L, Kim HG, Ghannoum MA. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int. J. Antimicrob. Agents 33(2), 149-153 (2009).
58. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. 194(5), 710-713 (2006).
59. de Brucker K, Bink A, Meert E, Cammue BPA, Thevissen K. Potentiation of antibiofilm activity of amphotericin b by superoxide dismutase inhibition. Oxid. Med. Cell. Longev. 2013, 704654. (2013).
60. Bal AM. The echinocandins: three useful choices or three too many? Int. J. Antimicrob. Agents 35(1), 13-18 (2010).
61. Denning DW. Echinocandin antifungal drugs. Lancet 362(9390), 1142-1151 (2003).
62. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53(1), 112-122 (2009).
63. Hao B, Cheng S, Clancy CJ, Nguyen MH. Caspofungin kills Candida albicans by causing both cellular apoptosis and necrosis. Antimicrob. Agents Chemother. 57(1), 326-332 (2013).
64. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71(1), 11-41 (2011).
65. Munro CA. Chitin and glucan, the yin and yang of the fungal cell wall, implications for antifungal drug discovery and therapy. Adv. Appl. Microbiol. 83, 145-172 (2013).
66. Kucharikova S, Tournu H, Lagrou K, Van Dijck P, Bujdakova H. Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. J. Med. Microbiol. 60(Pt 9), 1261-1269 (2011).
67. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J. Antimicrob. Chemother. 64(3), 567-570 (2009).
68. Culakova H, Dzugasova V, Gbelska Y, Subik J. CTBT (7-chlorotetrazolo[5,1- c]benzo[1,2,4] triazine) producing ROS affects growth and viability of filamentous fungi. FEMS Microbiol. Lett. 328(2), 138-143 (2012).
69. Batova M, Klobucnikova V, Oblasova Z et al. Chemogenomic and transcriptome analysis identifies mode of action of the chemosensitizing agent CTBT (7-chlorotetrazolo[5,1-c]benzo[1,2,4]triazine). BMC Genomics 11, 153 (2010).
70. Berila N, Hyrossova P, Subik J. Oxidative stress response and virulence factors in Candida glabrata clinical isolates. Folia Microbiol. (Praha) 56(2), 116-121 (2011).
71. Kang K, Wong KS, Fong WP, Tsang PW. Metergoline-induced cell death in Candida krusei. Fungal Biol. 115(3), 302-309 (2011).
72. Cheng J, Park TS, Chio LC, Fischl AS, Ye XS. Induction of apoptosis by sphingoid long-chain bases in Aspergillus nidulans. Mol. Cell. Biol. 23(1), 163-177 (2003).
73. Thevissen K, Hillaert U, Meert Em et al. Fungicidal activity of truncated analogues of dihydrosphingosine. Bioorg. Med. Chem. Lett. 18(13), 3728-3730 (2008).
74. Francois IE, Thevissen K, Pellens K et al. Design and synthesis of a series of piperazine-1-carboxamidine derivatives with antifungal activity resulting from accumulation of endogenous reactive oxygen species. ChemMedChem 4(10), 1714-1721 (2009).
75. Sigle HC, Schafer-Korting M, Korting HC, Hube B, Niewerth M. In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses 49(3), 159-168 (2006).
76. Miao H, Zhao L, Li C et al. Inhibitory effect of Shikonin on Candida albicans growth. Biol. Pharm. Bull. 35(11), 1956-1963 (2012).
77. Hwang JH, Hwang IS, Liu QH, Woo ER, Lee DG. (+)-Medioresinol leads to intracellular ROS accumulation and mitochondria-mediated apoptotic cell death in Candida albicans. Biochimie 94(8), 1784-1793 (2012).
78. Park C, Woo ER, Lee DG. Antifungal effect with apoptotic mechanism(s) of Styraxjaponoside C. Biochem. Biophys. Res. Commun. 390(4), 1255-1259 (2009).
79. Hwang IS, Lee J, Jin HG, Woo ER, Lee DG. Amentoflavone stimulates mitochondrial dysfunction and induces apoptotic cell death in Candida albicans. Mycopathologia 173(4), 207-218 (2012).
80. Tian J, Ban X, Zeng H, He J, Chen Y, Wang Y. The mechanism of antifungal action of essential oil from dill (Anethum graveolens L.) on Aspergillus flavus. PLoS ONE 7(1), e30147 (2012).
81. Chen Y, Zeng H, Tian J, Ban X, Ma B, Wang Y. Antifungal mechanism of essential oil from Anethum graveolens seeds against Candida albicans. J. Med. Microbiol. 62(Pt 8), 1175-1183 (2013).
82. Sharma M, Manoharlal R, Puri N, Prasad R. Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in Candida albicans. Biosci. Rep. 30(6), 391-404 (2010).
83. Wu XZ, Chang WQ, Cheng AX, Sun LM, Lou HX. Plagiochin E, an antifungal active macrocyclic bis(bibenzyl), induced apoptosis in Candida albicans through a metacaspase-dependent apoptotic pathway. Biochim. Biophys. Acta 1800(4), 439-447 (2010).
84. Wu XZ, Cheng AX, Sun LM, Sun SJ, Lou HX. Plagiochin E, an antifungal bis(bibenzyl), exerts its antifungal activity through mitochondrial dysfunction-induced reactive oxygen species accumulation in Candida albicans. Biochim. Biophys. Acta 1790(8), 770-777 (2009).
85. Dai BD, Cao YY, Huang S et al. Baicalein induces programmed cell death in Candida albicans. J. Microbiol. Biotechnol. 19(8), 803-809 (2009).
86. Aerts AM, Carmona-Gutierrez D, Lefevre S et al. The antifungal plant defensin RsAFP2 from radish induces apoptosis in a metacaspase independent way in Candida albicans. FEBS Lett. 583(15), 2513-2516 (2009).
87. Aerts AM, Bammens L, Govaert G et al. The antifungal plant defensin HsAFP1 from Heuchera sanguinea induces apoptosis in Candida albicans. Front. Microbiol. 2, 47 (2011).
88. Mello EO, Ribeiro SF, Carvalho AO et al. Antifungal activity of PvD1 defensin involves plasma membrane permeabilization, inhibition of medium acidification, and induction of ROS in fungi cells. Curr. Microbiol. 62(4), 1209-1217 (2011).
89. De Brucker K, Cammue BPA, Thevissen K. Apoptosis-inducing antifungal peptides and proteins. Biochem. Soc. Trans. 39(5), 1527-1532 (2011).
90. Hwang B, Hwang JS, Lee J, Lee DG. The antimicrobial peptide, psacotheasin induces reactive oxygen species and triggers apoptosis in Candida albicans. Biochem. Biophys. Res. Commun. 405(2), 267-271 (2011).
91. Cho J, Lee DG. The antimicrobial peptide arenicin-1 promotes generation of reactive oxygen species and induction of apoptosis. Biochim. Biophys. Acta 1810(12), 1246-1251 (2011).
92. Cho J, Lee DG. Oxidative stress by antimicrobial peptide pleurocidin triggers apoptosis in Candida albicans. Biochimie 93(10), 1873-1879 (2011).
93. Hwang B, Hwang JS, Lee J et al. Induction of yeast apoptosis by an antimicrobial peptide, Papiliocin. Biochem. Biophys. Res. Commun. 408(1), 89-93 (2011).
94. Park C, Lee DG. Melittin induces apoptotic features in Candida albicans. Biochem. Biophys. Res. Commun. 394(1), 170-172 (2010).
95. Helmerhorst EJ, Troxler RF, Oppenheim FG. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc. Natl Acad. Sci. USA 98(25), 14637-14642 (2001).
96. Andres MT, Viejo-Diaz M, Fierro JF. Human lactoferrin induces apoptosis-like cell death in Candida albicans: critical role of K+-channel-mediated K+ efflux. Antimicrob. Agents Chemother. 52(11), 4081-4088 (2008).
97. Veerman EC, Nazmi K, Van't Hof W, Bolscher JG, Den Hertog AL, Amerongen AV. Reactive oxygen species play no role in the Candidacidal activity of the salivary antimicrobial peptide histatin 5. Biochem. J. 381(Pt 2), 447-452 (2004).
98. Wunder D, Dong J, Baev D, Edgerton M. Human salivary histatin 5 fungicidal action does not induce programmed cell death pathways in Candida albicans. Antimicrob. Agents Chemother. 48(1), 110-115 (2004).
99. Lupetti A, Paulusma-Annema A, Senesi S, Campa M, Van Dissel JT, Nibbering PH. Internal thiols and reactive oxygen species in candidacidal activity exerted by an N-terminal peptide of human lactoferrin. Antimicrob. Agents Chemother. 46(6), 1634-1639 (2002).
100. Maurya IK, Pathak S, Sharma M et al. Antifungal activity of novel synthetic peptides by accumulation of reactive oxygen species (ROS) and disruption of cell wall against Candida albicans. Peptides 32(8), 1732-1740 (2011).
101. Konopka K, Dorocka-Bobkowska B, Gebremedhin S, Duzgunes N. Susceptibility of Candida biofilms to histatin 5 and fluconazole. Antonie Van Leeuwenhoek 97(4), 413-417 (2010).
102. Venkatesh M, Rong L, Raad I, Versalovic J. Novel synergistic antibiofilm combinations for salvage of infected catheters. J. Med. Microbiol. 58(Pt 7), 936-944 (2009).
103. Delattin N, Bardiot D, Marchand A et al. Identification of fungicidal 2,6-disubstituted quinolines with activity against Candida biofilms. Molecules 17(10), 12243-12251 (2012).
104. Yao B, Ji H, Cao Y et al. Synthesis and antifungal activities of novel 2-aminotetralin derivatives. J. Med. Chem. 50(22), 5293-5300 (2007).
105. Liang RM, Cao YB, Fan KH et al. 2-amino-nonyl-6-methoxyl-tetralin muriate inhibits sterol C-14 reductase in the ergosterol biosynthetic pathway. Acta Pharmacol. Sin. 30(12), 1709-1716 (2009).
106. Liang RM, Cao YB, Zhou YJ et al. Transcriptional response of Candida albicans biofilms following exposure to 2-amino-nonyl-6-methoxyl-tetralin muriate. Acta Pharmacol. Sin. 31(5), 616-628 (2010).
107. Thibane VS, Kock JL, Ells R, Van Wyk PW, Pohl CH. Effect of marine polyunsaturated fatty acids on biofilm formation of Candida albicans and Candida dubliniensis. Mar. Drugs 8(10), 2597-2604 (2010).
108. Thibane VS, Ells R, Hugo A et al. Polyunsaturated fatty acids cause apoptosis in C. albicans and C. dubliniensis biofilms. Biochim. Biophys. Acta 1820(10), 1463-1468 (2012).
109. Bink A, Pellens K, Cammue BPA, Thevissen K. Anti-biofilm strategies: how to eradicate Candida biofilms? Open Mycol. J. 5, 29-38 (2011).
110. Pereira Gonzales F, Maisch T. Photodynamic inactivation for controlling Candida albicans infections. Fungal Biol. 116(1), 1-10 (2012).
111. Sun Y, Yu S, Sun P et al. Inactivation of Candida biofilms by nonthermal plasma and its enhancement for fungistatic effect of antifungal drugs. PLoS ONE 7(7), e40629 (2012).
112. Fricke K, Koban I, Tresp H et al. Atmospheric pressure plasma. a high-performance tool for the efficient removal of biofilms. PLoS ONE 7(8), e42539 (2012).
113. Andrade MC, Ribeiro AP, Dovigo LN et al. Effect of different pre-irradiation times on curcumin-mediated photodynamic therapy against planktonic cultures and biofilms of Candida spp. Arch. Oral. Biol. doi:10.1016/j. archoralbio.2012.10.011 (2013) (Epub ahead of print).
114. Dovigo LN, Pavarina AC, Carmello JC, Machado AL, Brunetti IL, Bagnato VS. Susceptibility of clinical isolates of Candida to photodynamic effects of curcumin. Lasers Surg. Med. 43(9), 927-934 (2011).
115. Wysocki R, Kron SJ. Yeast cell death during DNA damage arrest is independent of caspase or reactive oxygen species. J. Cell Biol. 166(3), 311-316 (2004).
116. Enoksson M, Salvesen Gs. Metacaspases are not caspases-always doubt. Cell Death Differ. 17(8), 1221 (2010).
117. Carmona-Gutierrez D, Frohlich KU, Kroemer G, Madeo F. Metacaspases are caspases. Doubt no more. Cell Death Differ. 17(3), 377-378 (2010).
118. Lebrasseur N. Yeast apoptosis debate continues. J. Cell. Biol. 166, 938 (2004).
119. Fu Z, Lu H, Zhu Z, Yan L, Jiang Y, Cao Y. Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis. Biol. Pharm. Bull. 34(2), 214-218 (2011).
120. An M, Shen H, Cao Y et al. Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans. Int. J. Antimicrob. Agents 33(3), 258-263 (2009).
121. Okamoto Y, Aoki S, Mataga I. Enhancement of amphotericin B activity against Candida albicans by superoxide radical. Mycopathologia 158(1), 9-15 (2004).
122. Sharma M, Manoharlal R, Negi AS, Prasad R. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Res. 10(5), 570-578 (2010).
123. Kim JH, Faria NC, Martins ML, Chan KL, Campbell BC. Enhancement of antimycotic activity of amphotericin B by targeting the oxidative stress response of Candida and Cryptococcus with natural dihydroxybenzaldehydes. Front. Microbiol. 3, 261 (2012).
124. Xu Y, Wang Y, Yan L et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans. endogenous ROS augmentation. J. Proteome Res. 8(11), 5296-5304 (2009).
125. Seneviratne CJ, Wang Y, Jin L, Abiko Y, Samaranayake LP. Candida albicans biofilm formation is associated with increased anti-oxidative capacities. Proteomics 8(14), 2936-2947 (2008).
126. Wei GX, Xu X, Wu CD. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Arch. Oral Biol. 56(6), 565-572 (2011).
127. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9(9), 719-727 (2010).
128. Roemer T, Xu D, Singh SB et al. Confronting the challenges of natural product-based antifungal discovery. Chem. Biol. 18(2), 148-164 (2011).
129. Krysan DJ, Didone L. A high-throughput screening assay for small molecules that disrupt yeast cell integrity. J. Biomol. Screen. 13(7), 657-664 (2008).
130. Tebbets B, Stewart D, Lawry S et al. Identification and characterization of antifungal compounds using a Saccharomyces cerevisiae reporter bioassay. PLoS ONE 7(5), e36021 (2012).
131. Zhou Y, Wang G, Li Y et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob. Agents Chemother. 56(6), 3250-3260 (2012).
132. Zeidler U, Bougnoux ME, Lupan A et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J. Antimicrob. Chemother. 68(6), 1285-1296 (2013).
133. Bink A, Kucharikova S, Neirinck B et al. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J. Infect. Dis. 206(11), 1790-1797 (2012).
134. Spitzer M, Griffiths E, Blakely KM et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7, 499 (2011).